163 related articles for article (PubMed ID: 33941627)
1. Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative.
Snee M; Cheeseman S; Thompson M; Riaz M; Sopwith W; Lacoin L; Chaib C; Manley Daumont M; Penrod JR; O'Donnell JC; Hall G
BMJ Open; 2021 May; 11(5):e043442. PubMed ID: 33941627
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative.
Snee M; Cheeseman S; Thompson M; Riaz M; Sopwith W; Lacoin L; Chaib C; Daumont MJ; Penrod JR; Hall G
BMJ Open; 2021 Sep; 11(9):e046396. PubMed ID: 34526333
[TBL] [Abstract][Full Text] [Related]
4. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.
Wallington M; Saxon EB; Bomb M; Smittenaar R; Wickenden M; McPhail S; Rashbass J; Chao D; Dewar J; Talbot D; Peake M; Perren T; Wilson C; Dodwell D
Lancet Oncol; 2016 Sep; 17(9):1203-16. PubMed ID: 27599138
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.
Gibson AJW; Li H; D'Silva A; Elegbede AA; Tudor RA; Otsuka S; Bebb DG; Cheung WY
Lung Cancer; 2019 Aug; 134():141-146. PubMed ID: 31319972
[TBL] [Abstract][Full Text] [Related]
6. Non-small cell lung cancer chemotherapy treatment outcomes and ethnicity: a twenty-year single-centre patterns of care study.
Nguyen H; Keenan R; Kennedy I; Lao C; Lawrenson R
N Z Med J; 2023 Nov; 136(1585):24-34. PubMed ID: 37956355
[TBL] [Abstract][Full Text] [Related]
7. A study of non small cell lung cancer (NSCLC) patients with brain metastasis: A single centre experience.
Hatton N; Samuel R; Riaz M; Johnson C; Cheeseman SL; Snee M
Cancer Treat Res Commun; 2023; 34():100673. PubMed ID: 36603538
[TBL] [Abstract][Full Text] [Related]
8. Patterns of chemotherapy use and outcomes in advanced non-small cell lung cancer by age in England: A retrospective analysis of the population-based Systemic Anti-Cancer Treatment (SACT) dataset.
Pilleron S; Morris EJA; Dodwell D; Franks KN
J Geriatr Oncol; 2023 Sep; 14(7):101581. PubMed ID: 37421786
[TBL] [Abstract][Full Text] [Related]
9. Palliative Systemic Therapy Given near the End of Life for Metastatic Non-Small Cell Lung Cancer.
Beaudet MÉ; Lacasse Y; Labbé C
Curr Oncol; 2022 Feb; 29(3):1316-1325. PubMed ID: 35323312
[TBL] [Abstract][Full Text] [Related]
10. Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer.
Oselin K; Pisarev H; Ilau K; Kiivet RA
BMC Cancer; 2021 Mar; 21(1):274. PubMed ID: 33722202
[TBL] [Abstract][Full Text] [Related]
11. Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe.
Hofmarcher T; Lindgren P; Wilking N
J Cancer Policy; 2022 Dec; 34():100362. PubMed ID: 36087918
[TBL] [Abstract][Full Text] [Related]
12. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
13. Thirty-day mortality after systemic anticancer treatment as a real-world, quality-of-care indicator: the Northland experience.
Ang E; Newton LV
Intern Med J; 2018 Apr; 48(4):403-408. PubMed ID: 28872748
[TBL] [Abstract][Full Text] [Related]
14. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
15. Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic.
Kiss Z; Gálffy G; Müller V; Moldvay J; Sárosi V; Pápai-Székely Z; Csada E; Kerpel-Fronius A; Király Z; Szász Z; Hódi G; Polányi Z; Kovács K; Karamousouli E; Knollmajer K; Szabó TG; Berta A; Vokó Z; Rokszin G; Abonyi-Tóth Z; Barcza Z; Tamási L; Bogos K
Front Oncol; 2023; 13():1207295. PubMed ID: 37860193
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
Pan IW; Mallick R; Dhanda R; Nadler E
Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib.
McGrath AC; Sandhu G; Walpole E; McCaffrey E; Hollingworth SA
Anticancer Drugs; 2018 Sep; 29(8):786-790. PubMed ID: 30110016
[TBL] [Abstract][Full Text] [Related]
18. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
Okamoto I; Morita S; Tashiro N; Imamura F; Inoue A; Seto T; Yamamoto N; Ohe Y; Nakagawa K; Fukuoka M
Lung Cancer; 2018 Mar; 117():14-19. PubMed ID: 29496250
[TBL] [Abstract][Full Text] [Related]
19. Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort.
Noonan K; Tong KM; Laskin J; Melosky B; Sun S; Murray N; Ho C
Lung Cancer; 2014 Dec; 86(3):344-9. PubMed ID: 25439436
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
